New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:13 EDTBMRNBioMarin says change ups chance to hit cognition endpoint, says Janney Capital
Janney Capital noted that BioMarin's PEG-PAL study has been changed in terms of entry criteria, which will delay study results. However, the firm said management acknowledged that they think this change increases the chance of the study hitting the cognition endpoint, which Janney believes would strengthen the drug’s label and commercial outlook if it occurs. Janney has a Buy rating on BioMarin.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
18:20 EDTBMRNOn The Fly: After Hours Movers
UP AFTER EARNINGS: TubeMogul (TUBE), up 31.8% after reporting better than expected second quarter results and guidance above analyst estimates... Aruba Networks (ARUN), up 2.3% after reporting quarterly results and announcing a 3.7% workforce reduction... HEICO (HEI), up 2.3% after raising fiscal 2014 net income guidance. ALSO HIGHER: Chemtura (CHMT) and Diebold (DBD) are both up marginally after Mario Gabelli commented on the companies in an interview with CNBC. DOWN AFTER EARNINGS: Smith & Wesson (SWHC), down 10.2% after reporting disappointing first quarter results and lowering fiscal 2014 outlook. ALSO LOWER: Sturm, Ruger (RGR), down 4% after Smith & Wesson reported quarterly results... BioMarin (BMRN), down 1.35 after lowering fiscal 2014 revenue guidance.
16:36 EDTBMRNBioMarin lowers FY14 revenue view to $680M-$700M from $745M-$765M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use